Results 261 to 270 of about 59,126 (309)

Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis

Chien‐Wei Huang, Tse‐Ying Huang, Yafei Yang, Li‐Yang Chang, Yu‐Kang Tu, Vin‐Cent Wu, Jui‐Yi Chen   +6 more
openalex   +1 more source

Outpatient loop diuretic use and the effect of natriuresis‐guided diuretic therapy: A prespecified sub‐analysis of the PUSH‐AHF study

European Journal of Heart Failure, EarlyView.
The effects of natriuresis‐guided diuretic therapy in patients with acute decompensated heart failure, depending on outpatient loop diuretic use. HR, hazard ratio; NG, natriuresis‐guided; SOC, standard of care. Aims Diuretic resistance is frequently observed in patients with acute decompensated heart failure (ADHF), specifically in those with chronic ...
Lara E.E.C. Zonneveld, Iris E. Beldhuis, Hailun Qin, Dirk J. van Veldhuisen, Jenifer E. Coster, Wybe Nieuwland, Jan A. Krikken, Peter van der Meer, Adriaan A. Voors, Kevin Damman, Jozine M. ter Maaten   +10 more
wiley   +1 more source

Mineralocorticoid Receptor Antagonists and Cognitive Outcomes in Cardiovascular Disease and Beyond: A Systematic Review. [PDF]

J Pers Med
Pastena P, Campagnoli G, Rahmani AR, Kalogeropoulos AP.   +3 more
europepmc   +1 more source

Finerenone in patients with severe heart failure: The FINEARTS‐HF trial

European Journal of Heart Failure, EarlyView.
Severe heart failure and treatment with finerenone. CI, confidence interval; CV, cardiovascular; HF, heart failure; LVEF, left ventricular ejection fraction; RR, rate ratio. Aims While patients with severe heart failure (HF) were historically considered to have reduced left ventricular ejection fraction (LVEF), it is increasingly recognized that severe
Riccardo M. Inciardi, Henri Lu, Brian L. Claggett, Akshay S. Desai, Pardeep S. Jhund, Alasdair D. Henderson, Carolyn S.P. Lam, Bela Merkely, Michael Zi Miao, Michele Senni, Sanjiv J. Shah, Kavita Sharma, Orly Vardeny, Mark C. Petrie, Subodh Verma, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Flaviana Amarante, James Lay‐Flurrie, Andrea Glasauer, Andrea Scalise, John J.V. McMurray, Muthiah Vaduganathan, Scott D. Solomon   +24 more
wiley   +1 more source

Steroidal Mineralocorticoid Receptor Antagonist Side Effects and Reasons for Discontinuation: A Patient Survey (RELICS-PS). [PDF]

Pragmat Obs Res
Richard EL, Stephenson JJ, Desai NR, Willey VJ, Gay A, Scott C, Folkerts K, Pessina E, Singh R, Teng CC, Oberprieler NG.   +10 more
europepmc   +1 more source

The addition of vericiguat to sacubitril/valsartan improved the composite endpoint. Add a finishing touch on heart failure medical therapy by vericiguat as secret ingredient

European Journal of Heart Failure, EarlyView.
Haruyuki Kinoshita, Hiroshi Sugino, Masashi Kodama, Misato Saito, Yoji Sumimoto, Kenji Masada, Takashi Shimonaga, Akiyo Suga, Mayumi Toko, Kaori Taniyasu, Saki Ushirozako, Yumiko Katayama, Chiemi Hirahara, Masahiro Takada   +13 more
wiley   +1 more source

Adherence to guideline‐directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy

European Journal of Heart Failure, EarlyView.
Heart failure (HF) affects over 60 million individuals globally. Contemporary guideline‐directed medical therapies (GDMT) reduce cardiovascular mortality and HF hospitalizations. However, medication non‐adherence represents a critical barrier limiting real‐world efficacy of GDMT.
Gianluigi Savarese, Felix Lindberg, Antonio Cannata, Marianna Adamo, Giuseppe Ambrosio, Pietro Ameri, Markus S. Anker, Magnus Bäck, Antoni Bayes‐Genis, Tuvia Ben Gal, Frieder Braunschweig, Ovidiu Chioncel, Emilia D'Elia, Hassan El‐Tamimi, Gerasimos Filippatos, Nicolas Girerd, Loreena Hill, Ewa Jankowska, Kamlesh Khunti, Basil S. Lewis, Brenda Moura, Offer Amir, Stefania Paolillo, Massimo Piepoli, Abdulla Shehab, Maggie Simpson, Hadi Skouri, Davide Stolfo, Carlo Gabriele Tocchetti, Cristiana Vitale, Maurizio Volterrani, Stephan von Haehling, Sven Wassmann, Mehmet Birhan Yilmaz, Juan Carlos Kaski, Dobromir Dobrev, Marco Metra, Giuseppe M.C. Rosano   +37 more
wiley   +1 more source

Sodium–glucose co‐transporter 2 inhibitors in severe estimated glomerular filtration rate deterioration across cardiovascular‐kidney‐ metabolic conditions: A pooled analysis of randomized trials

European Journal of Heart Failure, EarlyView.
Aims The efficacy of sodium–glucose co‐transporter 2 inhibitors (SGLT2i) among patients with cardiovascular‐kidney‐metabolic (CKM) conditions who experience severe estimated glomerular filtration rate (eGFR) deterioration during follow‐up is not well established.
João Pedro Ferreira, Pedro Marques, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Abhinav Sharma, Francisco Vasques‐Nóvoa, Luís Mendonça, João Sérgio Neves, Milton Packer, Faiez Zannad   +10 more
wiley   +1 more source